Immunovant, Inc.
IMVT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IMVT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMVT
Immunovant, Inc. (IMVT) is a clinical-stage biotechnology company developing IMVT-1402, a novel FcRn inhibitor, for autoimmune diseases, with a lead focus on generalized myasthenia gravis (gMG) and thyroid eye disease (TED).
Key risk: Single-asset pipeline risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$8.51B
Cash Runway
19.6 moLead Asset
Batoclimab (Phase 2)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 15 clinical trials · 3 catalysts for Immunovant, Inc..
Immunovant, Inc. (IMVT) is a clinical-stage biotechnology company developing IMVT-1402, a novel FcRn inhibitor, for autoimmune diseases, with a lead focus on generalized myasthenia gravis (gMG) and thyroid eye disease (TED).
- Cash and equivalents of $797.8M as of June 30, 2026, expected to fund operations to potential commercial launch of IMVT-1402 in GD [sec_mda · as of 2026-08-06].
- Net loss of $153.2M for the quarter ended June 30, 2026, reflecting ongoing R&D investment [sec].
- Shareholders' equity of $852.6M as of June 30, 2026 [sec].
- Phase 2 topline data for IMVT-1402 in gMG expected by end of 2026, with Phase 3 topline readouts in gMG and TED anticipated in 2027 and 2028, respectively [catalyst].
What works
- Strong cash position of $797.8M as of June 30, 2026, providing runway to potential commercial launch [sec_mda · as of 2026-08-06].
- Focus on IMVT-1402, a next-generation FcRn inhibitor with potential best-in-class profile, after discontinuing batoclimab [sec_mda · as of 2026-08-06].
- Multiple late-stage catalysts approaching, including Phase 2 and Phase 3 readouts in gMG and TED [catalyst].
What to weigh
- Significant net loss of $153.2M in the latest quarter, with no approved products or revenue [sec].
- Reliance on a single pipeline asset (IMVT-1402) after discontinuing batoclimab, increasing development risk [sec_mda · as of 2026-08-06].
- Future capital requirements may increase with pipeline expansion, potentially requiring additional financing [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Cash runway to potential commercial launch
“We currently expect that our existing cash and cash equivalents as of June 30, 2026 of $797.8 million will be sufficient to fund our operating expenses and capital expenditure requirements, based on our current operating plan, to the potential commercial launch of IMVT-1402 in GD.”
SEC MD&A · August 6, 2026
Discontinuation of batoclimab to focus on IMVT-1402
“indefinitely delay further development of batoclimab and focus our resources fully on IMVT-1402.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · imvt-1402 — Phase 2 Readout: imvt-1402 — Topline data from the Phase 2 trial of IMVT-1402 in generalized myasthenia gravis will provide initial efficacy and safety signals.
- 2027-02-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficac — Phase 3 topline results for IMVT-1402 in generalized myasthenia gravis will be a key efficacy and safety readout.
- 2028-12-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy an — Phase 3 topline data for IMVT-1402 in thyroid eye disease will inform the potential registration path.
Risks & what to watch (4)›
Key risks
- Single-asset pipeline risk — After discontinuing batoclimab, IMVT-1402 is the sole pipeline candidate; any clinical setback would severely impact the company [sec_mda · as of 2026-08-06].
- Clinical trial failure risk — Phase 2 and Phase 3 readouts for IMVT-1402 in gMG and TED are pending; negative results could delay or halt development [catalyst].
- Future capital needs — Pipeline expansion may increase capital requirements beyond current cash, potentially requiring dilutive financing [sec_mda · as of 2026-08-06].
- Regulatory and competitive risk — FcRn inhibitor space is competitive; regulatory approval for IMVT-1402 is not guaranteed and may face delays [sec_mda · as of 2026-08-06].
What to watch
- Phase 2 topline data for IMVT-1402 in generalized myasthenia gravis (gMG) expected by end of 2026 [catalyst].
- Phase 3 topline readout for IMVT-1402 in gMG anticipated in early 2027 [catalyst].
- Phase 3 topline readout for IMVT-1402 in thyroid eye disease (TED) expected in late 2028 [catalyst].
- Any updates on pipeline expansion or additional development plans for IMVT-1402 in other indications [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Immunovant, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immunovant, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
19.6 months
D/E 0.16 · 0% dilution
Lead: Phase 2
2 candidates
3 upcoming, next in ~123d
0 buys · 39 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
215
Total value held
$2.79B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 16,947,888 | $421.0M |
| deep track capital, lp | 11,526,971 | $286.3M |
| vanguard capital management llc | 7,240,100 | $179.8M |
| blackrock, inc. | 6,574,497 | $163.3M |
| armistice capital, llc | 5,464,916 | $135.7M |
| baker bros. advisors lp | 5,457,881 | $135.6M |
| state street corp | 4,537,929 | $112.7M |
| woodline partners lp | 3,951,738 | $98.2M |
| morgan stanley | 3,876,877 | $96.3M |
| vanguard portfolio management llc | 3,704,905 | $92.0M |
Showing top 10 of 215 institutional holders of Immunovant, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 21.9%
- Days to cover
- 13.2
- Shares short
- 19,500,601
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMVT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Immunovant, Inc.?
Immunovant, Inc. (IMVT) is a clinical-stage biotechnology company developing IMVT-1402, a novel FcRn inhibitor, for autoimmune diseases, with a lead focus on generalized myasthenia gravis (gMG) and thyroid eye disease (TED).
What is Immunovant, Inc.'s lead drug candidate?
Immunovant, Inc.'s most advanced tracked candidate is Batoclimab (Phase 2) for Thyroid Eye Disease; Chronic Inflammatory Demyelinating Polyneuropathy.
What is Immunovant, Inc.'s next catalyst?
Immunovant, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: imvt-1402" — expected December 31, 2026.
Who is the CEO of Immunovant, Inc.?
Dr. Eric Venker M.D., Pharm.D. is the chief executive officer of Immunovant, Inc. (IMVT).
Where is Immunovant, Inc. headquartered?
Immunovant, Inc. (IMVT) is headquartered in Durham, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.